Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies

doi:10.3390/cancers5030919

Due to scheduled maintaince work on one of the switches in our server center, our websites www.mdpi.com and susy.mdpi.com may experience short service dirsuptions of up to 5 minutes on 30 January 2015 00:00 PM EST time.

Open AccessThis article is

freely available
re-usable

Cancers 2013, 5(3), 919-942; doi:10.3390/cancers5030919

Review

Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies

Antonino Grassadonia¹

, Pasquale Cioffi²

, Felice Simiele²

, Laura Iezzi³

, Marinella Zilli³

and Clara Natoli^1,*

+ Authors' affiliations

Received: 22 April 2013 / Revised: 3 July 2013 / Accepted: 12 July 2013 / Published: 25 July 2013

(This article belongs to the Special Issue Cancer Epigenetics)

View Full-Text | Download PDF [371 KB, uploaded 25 July 2013] | Browse Figures

Abstract: Hydroxamate-based histone deacetylase inhibitors (Hb-HDACIs), such as vorinostat, belinostat and panobinostat, have been previously shown to have a wide range of activity in hematologic malignancies such as cutaneous T-cell lymphoma and multiple myeloma. Recent data show that they synergize with a variety of cytotoxic and molecular targeted agents in many different solid tumors, including breast, prostate, pancreatic, lung and ovarian cancer. Hb-HDACIs have a quite good toxicity profile and are now being tested in phase I and II clinical trials in solid tumors with promising results in selected neoplasms, such as hepatocarcinoma. This review will focus on their clinical activity and safety in patients with advanced solid neoplasms.

Keywords: hydroxamate-based histone deacetylase inhibitors; histone deacetylase inhibitors; vorinostat; belinostat; panobinostat; pracinostat; abexinostat; resminostat

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX | EndNote

MDPI and ACS Style

Grassadonia, A.; Cioffi, P.; Simiele, F.; Iezzi, L.; Zilli, M.; Natoli, C. Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies. Cancers 2013, 5, 919-942.

AMA Style

Grassadonia A, Cioffi P, Simiele F, Iezzi L, Zilli M, Natoli C. Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies. Cancers. 2013; 5(3):919-942.

Chicago/Turabian Style

Grassadonia, Antonino; Cioffi, Pasquale; Simiele, Felice; Iezzi, Laura; Zilli, Marinella; Natoli, Clara. 2013. "Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies." Cancers 5, no. 3: 919-942.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert